Filters (2)
June 12, 2021

Safety and efficacy of CD37-targeting naratuximab emtansine plus rituximab in diffuse large B-cell lymphoma and other Non-Hodgkin’s B-cell lymphomas –…

Read more
March 23, 2021

Is CD37-targeted therapy a viable alternative in the treatment of diffuse large B-cell lymphoma? Interviews with two key opinion leaders

Read more
April 16, 2018

Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMGN529/DEBIO1562 in diffuse large B-cell…

Read more